MedChem 2018

New Avenues in Kinase Drug Discovery: a Bright Future ?

Annual One-Day Meeting on Medicinal Chemistry of SRC & KVCV

 Namur, Belgium    November 23, 2018

Programme


08:00

Registration

Session Chair

Dr Laurent PROVINS
UCB, Braine-l'Alleud, Belgium

08:50

Opening

Dr Laurent PROVINS
UCB, Braine-l'Alleud, Belgium

09:00

PL01 - Kinase Inhibitors for Non-oncological Indications: Is there a Future ?

Dr Doriano FABBRO
PIQUR THERAPEUTICS, Basel , Switzerland

09:50

PL02 - Chemoinformatics-Driven View of Kinase Drug Discovery
(Lecture sponsored by ChemMedChem)

Prof. Jürgen BAJORATH
UNIVERSITY OF BONN, Bonn, Germany

10:40

Coffee break and Exhibition

Session Chair

Prof. Johan WOUTERS
UNAMUR, Namur, Belgium

11:15

OC01 - A Fast in Silico Fragment-Based Design Tool for the Discovery of Novel Kinase Inhibitors

Prof. Pascal BONNET
UNIVERSITY OF ORLÉANS, Orléans, France

11:35

PL03 - Fragment Based Drug Discovery of Selective Inhibitors of Fibroblast Growth Factor Receptors

Dr Patrick ANGIBAUD
JANSSEN R&D, Val de Reuil, France

12:25

Lunch, Exhibition and Poster session

Session Chair

Prof. Raphaël FREDERICK
UCLOUVAIN, Bruxelles-Woluwé, Belgium

14:00

PL04 - Discovery, Development and In Vivo Profiling of a Novel Class of Immunosuppressive PI4KIIIβ Lipid Kinase Inhibitors

Dr James REUBERSON
UCB, Slough, United Kingdom

14:50

OC02 - Discovery And Development Of Highly Potent And Selective FLT3 Kinase Inhibitors, A New Class of Peripheral Drugs for Treating Neuropathic Pain

Dr Claire AMIABLE
BCI PHARMA, Montpellier, France

15:10

OC03 - Imidazo[4,5-B]Pyridine Derivatives as Potent Tam Inhibitors: From Synthesis To Cellular Imaging

Dr Sandrine PIGUEL
INSTITUT CURIE, Orsay, France

15:30

Coffee break, Exhibition and Poster session

Session Chair

Dr Lionel POCHET
UNAMUR, Namur, Belgium

16:05

PL05 - CDK8 Inhibitors with Pre-Engineered Long Residence Time: From Design to Tumor Xenograft Models

Dr Koen HEKKING
MERCACHEM-SYNCOM, Nijmegen, The Netherlands

16:45

PL06 - PTEFb/CDK9 Inhibitor BAY 1251152 for the Treatment of Cancer

Dr Ulrich LÜCKING
BAYER HEALTHCARE, Berlin, Germany

17:35

Closing Remarks

Prof. Koen AUGUSTYNS
UNIVERSITY OF ANTWERP, Antwerp, Belgium